Peng Yan

Dr. Peng Yan


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 July 2020 in Survey of Ophthalmology
Verified
Journal Article
Closed access
SYShanna C. Yeung
Shanna C. Yeung
YYYuyi You
Yuyi You
KHKathryn L. Howe
Kathryn L. Howe
PYPeng Yan
Peng Yan

19 April 2022 in Survey of Ophthalmology
Verified
Journal Article
Closed access
KMKian Madjedi
Kian Madjedi
APAustin Pereira
Austin Pereira
BBBrian G Ballios
Brian G Ballios
PAParnian Arjmand
Parnian Arjmand
PKPeter J. Kertes
Peter J. Kertes
PYPeng Yan
Peng Yan

1 November 2021 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
PFParsa Mehraban Far
Parsa Mehraban Far
SYShanna C. Yeung
Shanna C. Yeung
PMPatrick E. Ma
Patrick E. Ma
BHBernard Hurley
Bernard Hurley
PKPeter Kertes
Peter Kertes
PYPeng Yan
Peng Yan

14 May 2021 in Retina
Verified
Journal Article
Closed access
PFParsa Mehraban Bhsc. Far
Parsa Mehraban Bhsc. Far
SYShanna C Md(C) Yeung
Shanna C Md(C) Yeung
PFPedram Laghaei Bsc. Farimani
Pedram Laghaei Bsc. Farimani
JQJenny Qian
Jenny Qian
AZAngela Q. Zhang
Angela Q. Zhang
PYPeng Yan
Peng Yan
Purpose: To compare the visual outcomes after prompt pars plana vitrectomy (PPV) with tap biopsy and intravitreal antimicrobial injection to treat postinjection and postsurgery endophthalmitis. Methods: The Cochrane Central Register of Controlled Trials, Ovid MEDLINE, and Ovid Embase databases were searched for articles published between January 2010 and November 2020. Two independent reviewers selected articles and extracted data. We analyzed data in RevMan 5.3 and assessed methodological quality using the Cochrane ROBINS-I tool. The mean improvement in visual outcome was compared between PPV and intravitreal antimicrobial injection as a relative risk of improving ≥2 lines and a mean logarithm of the minimal angle of resolution difference in improvement. Results: Fifteen retrospective case series (1,355 eyes), of which 739 eyes (55%) received intravitreal antimicrobial injection and 616 (45%) received PPV as initial treatment, were included. The overall relative risk of improving 2 or more lines in PPV in comparison with intravitreal antimicrobial injection was 1.04 (95% CI 0.88–1.23; P = 0.61; I2 = 0%) with a mean difference of 0.04 (95% CI −0.18 to 0.27; P = 0.69; I2 = 0%). The results stayed robust when subgroup analysis based on causative procedure for endophthalmitis was performed. Conclusion: Intravitreal antimicrobial injection is noninferior to PPV for the treatment of postcataract operation, postinjection, and post-PPV endophthalmitis.

13 August 2022 in Survey of Ophthalmology
Verified
Journal Article
Closed access
JIJames H.B. Im
James H.B. Im
YJYa-Ping Jin
Ya-Ping Jin
RCRonald Chow
Ronald Chow
RDRiddhi Shah Dharia
Riddhi Shah Dharia
PYPeng Yan
Peng Yan